{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:11:11Z","timestamp":1790208671398,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2021\u20102\u201075"],"award-info":[{"award-number":["320.6750.2021\u20102\u201075"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non\u2010small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)\u2014tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combination therapy of programmed death 1 (PD\u20101)\/programmed death ligand 1 (PD\u2010L1) inhibitors\u2009+\u2009anti\u2010angiogenesis. Recent treatment guidelines and clinical studies related to adenocarcinoma in NSCLC have indicated that in patients with inoperable stage IV lung adenocarcinoma, immune checkpoint inhibitors in combination with anti\u2010angiogenic drugs may exert a synergistic effect and significantly improve the efficacy of near\u2010term treatment, but quantification and long\u2010term follow\u2010up of specific clinical indicators are still lacking. No previous cases of long\u2010term good results with camrelizumab combined with anti\u2010angiogenic agents for KRAS\u2010mutated NSCLC have been described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>This manuscript reports a case of a patient with advanced NSCLC with pleural effusion and KRAS mutations treated poorly with conventional chemotherapy who had long\u2010term (more than 18\u2009months) benefit with immunotherapy combined with an anti\u2010angiogenic inhibitor in Shanghai General Hospital. In this case, pharmaceutical care of the patient was carried out through therapeutic drug adjustment, compliance, efficacy assessment, and safety evaluation to provide a reference for improving the efficacy and safety of drug therapy in clinical practice. As of the last follow\u2010up date (December 2023), overall survival was 27\u2009months, and the patient is currently in good general condition with no significant complaints of discomfort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICLs in combination with antiangiogenic therapy may be a therapeutic option for patients with KRAS mutations in advanced non\u2010small cell lung cancer with good persistence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70186","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T07:08:13Z","timestamp":1749452893000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Advanced\n                    <scp>IVB<\/scp>\n                    Lung Adenocarcinoma Patient With\n                    <scp>KRAS<\/scp>\n                    Mutations, Benefited From Camrelizumab Combined With Anti\u2010Angiogenic Agents for Therapy: A Case Report"],"prefix":"10.1002","volume":"8","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[{"name":"School of Pharmacy Shanghai Jiao Tong University  Shanghai China"},{"name":"Department of Clinical Pharmacy Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuping","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy EYE &amp; ENT Hospital of Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-9689","authenticated-orcid":false,"given":"Zhenghua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0063-y"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0019-2016"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002"},{"issue":"12","key":"e_1_2_11_6_1","first-page":"1063","article-title":"Expert Committee on Vessel Targeted Therapy of Chinese Society of Clinical Oncology, E.C.o.N.\u2010s.C.L.C.o.C.S.o.C.O., & Expert Group on Antiangiogenic Drugs for Non\u2010Small Cell Lung Cancer of Chinese Society of Clinical Oncology","volume":"42","year":"2020","journal-title":"Chinese Journal of Oncology"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20210259"},{"issue":"3","key":"e_1_2_11_8_1","article-title":"The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer","volume":"66","author":"Wu H.","year":"2020","journal-title":"Clinical Laboratory"},{"issue":"4","key":"e_1_2_11_9_1","first-page":"372","article-title":"Association of CEA, NSE, CYFRA 21\u20101, SCC\u2010Ag, and ProGRP With Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer","volume":"54","author":"Bi H.","year":"2023","journal-title":"Laboratoriums Medizin"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-019-0084-z"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109746"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360671"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03101-9"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S346635"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-250009"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13569"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634059"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13748"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12475"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms140611145"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1875"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-527"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0121"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0196"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.37966"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.909721"},{"issue":"4","key":"e_1_2_11_27_1","article-title":"Single or Combined Immune Checkpoint Inhibitors Compared to First\u2010Line Platinum\u2010Based Chemotherapy With or Without Bevacizumab for People With Advanced Non\u2010Small Cell Lung Cancer","volume":"4","author":"Ferrara R.","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.07.005"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T10:14:43Z","timestamp":1771323283000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/cnr2.70186"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70186","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70186"}}